Home / News / Progress in Personalised Medicine developing a novel biopharmaceutical, from bench to production

Progress in Personalised Medicine developing a novel biopharmaceutical, from bench to production

Together with Maastricht University and Lifeteczone, Basic Pharma organizes a symposium about the challenge in the development of biopharmaceuticals. REGISTER NOW!

DATE:	May 16
LOCATION:	Brightlands Chemelot Campus, Geleen (NL)
REGISTRATION:	www.lifeteczone.nl/nl/agenda

A major challenge in the development of biopharmaceuticals is achieving clinical grade products for clinical evaluation. Under the framework of the Interreg V Netherlands and Flanders -project SkiN-HUID, Basic Pharma and MosaMedix, Universities of Maastricht, Antwerp and the Flemish Institute for Biotechnology (VIB) at the KU Leuven joined forces.

SKiN-HUID develops a novel treatment of skin cancer that combines administration of a biopharmaceutical medicine targeting cancer cells and application of electrical and hyperthermal stimulation of the cancer that enhances the efficacy of the biopharmaceutical medicine.

Within SKiN-HUID the consortium aims to overcome the major hurdle of bringing a novel biopharmaceutical product to the clinic: the GMP-production of clinical grade biopharmaceutical medicine for the first phase of clinical studies. Basic Pharma set up a novel pilot plant for the GMP-production of biopharmaceutical medicines. This facility forms an essential part of the value chain linking preclinical and clinical evaluation of the efficacy of biopharmaceutical medicines.

Collaboration between University and Industry is paramount in mastering this challenge. We cordially invite you to join our mission in accelerating personalised medicine innovations.

12.00	Lunch
13.00	Welcome
13.10	Brightlands, a knowledge and technology hub to facilitate collaboration between Industry and University Bert Kip, Brightlands Chemelot Campus
13.20	SkiN-HUID, a euregional collaboration between Industry and Universities to improve the treatment of skin cancer. Chris Reutelingsperger, Maastricht University
13.35	Melanoma Patient-Derived Tumor Xenografts in mice as preclinical models to understand carcinogenesis and to predict efficacy of novel anticancer drugs Michael Dewaele, VIB Center for Cancer Biology KULeuven
13.55	The role of pathology in translating experimental treatments from the preclinic to clinical application. Jean Paul Bogers, University of Antwerp
14.20	GMP-production of biologicals for the first-in-man clinical study. Ralph Bosmans, Basic Pharma Technoliges B.V.
14.45	Regulatory aspects during (early) development of biopharmaceuticals Jacques Havermans, Interdos Pharma B.V.
15.10	SME pitches: Novel technologies in personalised medicine Matisse Pharmaceuticals BV- Geleen- Peter Ekhart Noviocell BV – Pivot Park Oss - Juliette van den Dolder …and more….
16.00	Networking
17.30	Closing

REGISTRATION
The meeting is especially of interest to companies active in biotechnology, pharmaceuticals and medical devices. You can register for the event free of charge (registration mandatory) via: www.lifeteczone.nl/nl/agenda/mei2019

Sign up for our newsletter

Sign up